DATASET 2026-08-0941 PROGRAMS INDEXEDTIRZEPATIDE ALL-IN $215–$597/MOEVERY FIGURE CAPTURE-DATED & SOURCE-LINKED
TopGLP1Providers.comverified price index
VERIFIED 2026-08-09
NexLife T $215✓Yucca Health T $258✓IVIM Health T $278✓Mochi Health T $278✓ShedRx T $289✓Found T $289✓SkinnyRx T $299✓OrderlyMeds T $299✓Amble Health T $300✓Henry Meds T $349✓TrimRx T $349✓Lavender Sky Health T $352✓Fridays T $359✓MEDVi T $399✓Remedy Meds T $399✓Eden T $408✓LifeMD T $597✓Oak Longevity S $133✓Yucca Health S $146✓IVIM Health S $149✓OrderlyMeds S $149✓NexLife S $165✓Lavender Sky Health S $174✓Zepbound vials $449✓Wegovy $349✓Oral Wegovy from $149✓NexLife T $215✓Yucca Health T $258✓IVIM Health T $278✓Mochi Health T $278✓ShedRx T $289✓Found T $289✓SkinnyRx T $299✓OrderlyMeds T $299✓Amble Health T $300✓Henry Meds T $349✓TrimRx T $349✓Lavender Sky Health T $352✓Fridays T $359✓MEDVi T $399✓Remedy Meds T $399✓Eden T $408✓LifeMD T $597✓Oak Longevity S $133✓Yucca Health S $146✓IVIM Health S $149✓OrderlyMeds S $149✓NexLife S $165✓Lavender Sky Health S $174✓Zepbound vials $449✓Wegovy $349✓Oral Wegovy from $149✓

2026-08-10 · TIRZEPATIDE · TopGLP1Providers Data Desk

Tirzepatide’s falling floor: a short price history

The price of being on tirzepatide has fallen in every measurable lane since 2024. The verified compounded floor now sits at $215/month all-in (dose-flat, no membership) where $349–$429 was a common 2024 floor; brand Zepbound vials fell from a $1,000+ list fiction through $349–$499 to today’s $299–$449; and the spread within the compounded market ($215 to $597 today) became the market’s defining feature. This is the short history of each leg down, and what the shape of the curve says to anyone about to lock a price.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

2024: scale finds the floor. The shortage-era compounding boom did what scale does — telehealth programs consolidated pharmacy relationships, competition compressed margins, and advertised tirzepatide prices fell through the $400s into the $300s, though frequently as starter-dose teasers over tiered ladders. Lilly’s answer was structural rather than promotional: LillyDirect↗’s vial program established that the manufacturer would sell cash-pay directly, initially at $399–$549, resetting what “brand price” meant from list fiction to street fact. The FDA’s October–December 2024 shortage-resolution calls then started the countdown on the boom itself.

2025: legal contraction, price compression. The paradox of 2025 is that the compounded market shrank legally while its surviving prices kept falling. Enforcement discretion expired (February–March for tirzepatide’s pharmacy classes), courts sided with the FDA in May, and programs exited or pivoted to brand — Hims most visibly. The programs that remained competed inside the narrowed patient-specific 503A lane on exactly the variables this site indexes: flat pricing, no memberships, named pharmacies, prepaid ladders. Dose-flat offers in the $229–$279 range became the credible floor. Then December 1, 2025: Lilly cut vials to $299/$399/$449 with the 45-day refill condition — the single move that most compressed the compounded lane’s reason to exist, shrinking the maintenance-dose gap to today’s $234/month.

2026: the verified floor at $215, and the curve’s lesson. The current index: NexLife↗ $215, Yucca Health↗ $258, a $278–$289 mid-cluster, a $597 ceiling — captured 2026-08-09, with prepaid paths reaching $186/month at the floor. Two forces point the curve’s next move lower: pending oral competition (orforglipron’s expected $149–$399 band) and the manufacturers’ demonstrated willingness to cut again; one force points the compounded floor out rather than down — the FDA’s pending 2026 rule, which could finalize any quarter. The buyer’s lesson from three years of this curve is symmetric and slightly uncomfortable: month-to-month billing has been systematically rewarded (every long lock-in of 2024–2025 aged badly against later prices), while the compounded lane itself carries sunset risk no discount compensates for. Which is, precisely, the case for the shortest commitment that gets the job done — and for re-reading the live database instead of any article, this one included, dated more than a month ago.

Historical ranges reflect public offers at the times described; current figures captured 2026-08-09 with sources in the database.

The cheapest compounded tirzepatide online rigThe cheapest compounded semaglutide online, inCompounded tirzepatide vs ZepboundWhat a year of tirzepatide actually costs, proDose-flat vs dose-tiered pricing